What is ABODATO and How Does It Help Treat Hair Loss?
ABODATO is a so-called second generation dihydrotestosterone (DHT) inhibitor produced by the pharmaceutical company GlaxoSmithKline. Like Finasteride (Propecia), it was developed to treat the enlargement of the prostate gland in men known as benign prostatic hyperplasia (BPH).
As was the case during Merck's Finasteride testing back in the 1990s, ABODATO's beneficial effects on hair loss became noticeable during GlaxoSmithKline's clinical trials of the drug as a treatment for BPH. ABODATO(アボダート) was granted FDA approval as a drug to treat BPH and appeared on the market in 2003 branded as Avodart.
For the purposes of treating BPH, the recommended dose is a 0.5 mg soft gel capsule which use once daily. ABODATO has not been approved by the FDA for the purposes of treating hair loss. If this ever occurs, like Finasteride it will only be approved for use by men.
ABODATO is a dual DHT inhibitor, meaning that it acts on both type I and type II of the enzyme 5-alpha-reductase. Its use can lead to a 93% reduction in the conversion of testosterone into DHT in the body. The executives of GlaxoSmithKline were uneasy about the fact that their DHT inhibitor was more powerful than Finasteride, despite the fact that this led to increased benefits as far as hair loss were concerned, the drug might be too strong for a nervous market in which Finasteride was already underperforming.
Still, this ABODATO(アボダート) could be the next systemic drug to be approved by the FDA to treat hair loss.
As was the case during Merck's Finasteride testing back in the 1990s, ABODATO's beneficial effects on hair loss became noticeable during GlaxoSmithKline's clinical trials of the drug as a treatment for BPH. ABODATO(アボダート) was granted FDA approval as a drug to treat BPH and appeared on the market in 2003 branded as Avodart.
For the purposes of treating BPH, the recommended dose is a 0.5 mg soft gel capsule which use once daily. ABODATO has not been approved by the FDA for the purposes of treating hair loss. If this ever occurs, like Finasteride it will only be approved for use by men.
ABODATO is a dual DHT inhibitor, meaning that it acts on both type I and type II of the enzyme 5-alpha-reductase. Its use can lead to a 93% reduction in the conversion of testosterone into DHT in the body. The executives of GlaxoSmithKline were uneasy about the fact that their DHT inhibitor was more powerful than Finasteride, despite the fact that this led to increased benefits as far as hair loss were concerned, the drug might be too strong for a nervous market in which Finasteride was already underperforming.
Still, this ABODATO(アボダート) could be the next systemic drug to be approved by the FDA to treat hair loss.
Comment
Welcome to
MyChillPills - Mental Health for the Masses
Wear Your Issues On Your Sleeve
Badge
© 2009 Created by Sean Bowen
You need to be a member of MyChillPills - Mental Health for the Masses to add comments!
Join this Ning Network